PMC9705570_01
CT scans, treatment history, and gene mutation of case 1 at different clinical time points as shown. CT scans results. (A) Chest CT scans of right lung adenocarcinoma and lymph nodes before first-line treatment. (B) PR was observed after gefitinib was added to the combined chemotherapy, second-line treatment. (C) The change of lung lesion before and after third-line treatment, anlotinib plus gefitinib. (D) CT scans before and after two cycles of terriprizumab plus bevacizumab, sixth-line treatment. (E) MRI of the brain. CR of LM was obtained after 1 month of furmonertinib, seventh-line treatment. (F) The lung and CNS lesions were kept stable until recent follow-up in April 2022. (G) The timeline of Case 1 treatment history, follow-up diagnostic and gene test results. Numbers indicate the time from the diagnosis of NSCLC. CR, complete response; PR, partial response; SD, stable disease, PD, progressive disease; CSF, cerebrospinal fluid; CNS, central nervous system; VAF, variant allele frequency.
fonc-12-957661-g001.jpg
PMC9705570_01_fonc-12-957661-g001.jpg
f1
A computed tomography (CT) of the patient's chest showed a mass in the right upper lung and diffuse micronodules in both lungs ( Figure 1A ). PR was achieved after gefitinib (250 mg once daily) was added to the treatment for two cycles ( Figure 1B ). PR was observed according to the CT scan ( Figure 1C ). PR was achieved after two cycles of treatment ( Figure 1D ). After 1 month of EGFR-TKI rechallenge, CR of intracranial lesions was further confirmed ( Figure 1E ). The patient had received furmonertinib for more than 6 months, and no evidence of malignancy recurrence was found by brain MRI ( Figure 1F ). The treatment history and gene test results of this patient are presented in  Figure 1G .
PMC9705570_02
CT scans, treatment history, and gene mutation of Case 2 at different clinical time points as shown. (A) Chest CT scans. PR was observed after durvalumab plus anlotinib, fourth-line treatment. (B) MRI of the brain. A PR of LM was obtained after two cycles of osimertinib rechallenge. (C) The lung and CNS lesion kept stable till recent follow-up in April 2022. (D) The timeline of Case 2 treatment history, follow-up diagnostic and gene test results. The numbers indicate the time from the diagnosis of NSCLC.
fonc-12-957661-g002.jpg
PMC9705570_02_fonc-12-957661-g002.jpg
f2
PR was observed after two cycles ( Figure 2A ). Figure 2B ). Finally, the osimertinib rechallenge was maintained for more than 11 months and the patient was still in close follow-up ( Figure 2C ). The treatment history and gene test results are presented in  Figure 2D .